Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › CareFirst BCBS to Cover Exosome Dx Prostate Cancer Test

CareFirst BCBS to Cover Exosome Dx Prostate Cancer Test

Jan 08, 2018
|
staff reporter

NEW YORK (GenomeWeb) – CareFirst Blue Cross Blue Shield said today that it will cover Exosome Diagnostics' ExoDx Prostate IntelliScore (EPI) prostate cancer test based on the results of an evidence development study launched last year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
26
Featured Webinar

Responding to Emerging SARS-CoV-2 Variants: The Impact on Existing Diagnostic Testing and the Clinical Utility of Differentiation Assays

As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.  

What's Popular?

In Molecular Diagnostics

  1. President Biden Announces Plan to Expand SARS-CoV-2 Testing, Increase Capacity

  2. Invitae to Raise $400M in Proposed Public Offering

  3. Natera Sues Inivata, Alleging Infringement of Cancer Testing Patents

  4. CareDx Prices $175M Common Stock Offering

  5. Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.